RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment
Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months
ODAC Votes 13:0 For Approving Perjeta
Early Treatment with CMX001 Can Help Prevent CMV Infection
Researchers Identify Mutation Linked to Inherited Risk of ALL
Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia
Avoiding the Hippocampus During Whole-Brain Radiotherapy Can Preserve Memory Function
Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy
Long-term Hormonal Therapy Adds No Additional Benefits
NCI CTEP Approved Trials For the Month of September
FDA Approves Generic Version Of Capecitabine for Metastatic Colorectal and Breast Cancer
Trending Stories
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Why both somatic and germline genomic profiling are essential for precision oncology
- Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?
